Navigation Links
Accera, Inc. Names William T. Poncy Vice President of Commercial Development
Date:10/10/2007

BROOMFIELD, Colo., Oct. 10 /PRNewswire/ -- Accera Inc., a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases, today announced that it has appointed William T. Poncy, M.B.A., as vice president of commercial development. Mr. Poncy will direct the commercial launch of Ketasyn (AC-1202) as a medical food product in the U.S. for the treatment of Alzheimer's disease.

"Given his strong track record in all aspects pharmaceutical commercialization, we are thrilled to welcome Bill to our management team," commented Steve Orndorff, Ph.D., president and CEO. "We are confident that his strong track record combined with Ketasyn's excellent safety and efficacy will allow Accera to make a competitive entry into the multi billion-dollar Alzheimer's market."

Additionally, Mr. Poncy will be responsible for developing Accera's neurodegenerative disease franchise for ethical drugs now in development for Parkinson's disease, Huntington's disease, and age-associated memory impairment.

With more than 25 years of experience in the pharmaceutical industry, Mr. Poncy most recently served as vice president of sales and marketing at Myogen, Inc. (now Gilead Sciences), where he built the commercial organization and launched a pulmonary anti-hypertension franchise. Previously he was the North American vice president of sales and marketing for Pharmion Corp., where he developed an oncology commercial organization. He has also held positions in sales, managed care, trade, marketing and various management roles at DuPont Pharmaceuticals and Berlex Labs.

About Accera, Inc.

Based in Broomfield, CO, Accera, Inc. is a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases. The company's lead candidate, Ketasyn(TM) (AC-1202), is a first-in-class molecule that earlier this year completed successful Phase II clinical trials for Alzheimer's disease (AD) and age-associated me
'/>"/>

SOURCE Accera Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Wisconsin IT association names Gee president, CEO
2. Quintessence Biosciences names new president
3. CDW names VP to handle Berbee merger
4. NimbleGen names CFO with capital-raising past
5. Cisco names Berbee a top partner of 2005
6. Cisco names Inacom most innovative partner
7. UW-Madison medical school names new dean
8. GE Healthcare names new CEO
9. Bruker AXS names new leadership
10. Sonic Foundry names new senior vice president
11. MyWeather names new president, marketing officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal ... been selected by Buffalo BioBlower Technologies LLC ("B3") as ... SBIR Phase 2 award from the Army Corps of ... system that kills all biological contaminants and destroys VOCs ...
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... A study has been launched to test whether technology ... help to tackle the problem of obesity.  This unique healthcare ... based in Stowmarket) and academics at University Campus Suffolk is ... which is inspired by equipment used to collect data about ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
Breaking Biology Technology:Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... atom quantum dots created by researchers at Canada,s National ... possible a new level of control over individual electrons, ... reach. Composed of a single atom of silicon ... are the smallest quantum dots ever created. ...
... Corporation (OTC Bulletin Board: ACEL) today reported that it ... and Drug Administration (FDA) to discuss the company,s planned ... New Drug Application (NDA) for the treatment of unresectable ... the FDA provided guidance to the company recommending that ...
... INFORMATION PUBLISHED BY UNIVERSAL , NETTLETON, Miss., Jan. ... announces that certain unauthorized inaccurate information is being ... BeaconEquity.com website, potentially other websites and publications, and ... the company has found errors in statements concerning ...
Cached Biology Technology:Smallest ever quantum dots bring real world applications closer 2Alfacell Provides ONCONASE(R) NDA Submission Update 2Alfacell Provides ONCONASE(R) NDA Submission Update 3
(Date:4/17/2014)... painted a stark warning on the possible effects of ... effect 32 times that of carbon dioxide. Now a ... act as fully regenerable electron acceptors which helps explain ... instead of being released to the atmosphere. However, there ... may enter into a vicious cycle to release large ...
(Date:4/17/2014)... full of wild animals and plant life, but there,s ... churning away in the soil, decomposing organic matter and ... role these fungi play in ecological systems, their identities ... scientists has generated a genetic map of more than ... was published this week in the Proceedings of ...
(Date:4/16/2014)... legal, artisanal green sea turtle fishery has uncovered a ... in what may have become an unsustainable take, according ... University of Florida. , During the research period, conservation ... killed between 1991 and 2011, with catch rates peaking ...
Breaking Biology News(10 mins):Methane climate change risk suggested by proof of redox cycling of humic substances 2Stanford biologists help solve fungal mysteries 2Stanford biologists help solve fungal mysteries 3Declining catch rates in Caribbean green turtle fishery may be result of overfishing 2Declining catch rates in Caribbean green turtle fishery may be result of overfishing 3
... A DNA-based study sheds new light on the complex evolutionary ... completely different and much larger species. The research, which ... Biology , found the woolly mammoth, which lived in the ... mammoth, which preferred the more temperate regions of North America ...
... Amsterdam, The Netherlands: Direct-to-consumer (DTC) genetic tests give ... believe that some of them should be banned, the ... will hear today (Tuesday). In the first of ... department of epidemiology at Erasmus University Medical Centre, Rotterdam, ...
... Amsterdam, The Netherlands: Pre-implantation genetic diagnosis (PGD) ... mitochondrial DNA disorder to their offspring a good chance ... child, a researcher told the annual conference of the ... Debby Hellebrekers, from Maastricht University Medical Centre, Maastricht, The ...
Cached Biology News:Researchers solve mammoth evolutionary puzzle: The woollies weren't picky, happy to interbreed 2DTC genetic tests neither accurate in their predictions nor beneficial to individuals 2DTC genetic tests neither accurate in their predictions nor beneficial to individuals 3DTC genetic tests neither accurate in their predictions nor beneficial to individuals 4PGD can permit the birth of healthy children to women carrying mitochondrial DNA disease 2
Anti-CoralHue Dronpa Green Monoclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Phospho-FKHR (Thr24)/FKHRL1 (Thr32) Antibody...
Prostaglandin-E2 receptor EP2/EP3 Market Segment: GPCRs...
... Antibody - Red, 20X ... antibody at 20X concentration for use ... assays. Quality Assurance ... FarRed fluorescence polarization assays. ...
Biology Products: